Literature DB >> 8789387

delta- and mu-opioid receptor mobilization of intracellular calcium in SH-SY5Y human neuroblastoma cells.

M Connor1, G Henderson.   

Abstract

1. In this study we have investigated delta and mu opioid receptor-mediated elevation of intracellular Ca2+ concentration ([Ca2+]i) in the human neuroblastoma cell line, SH-SY5Y. 2. The Ca(2+)-sensitive dye, fura-2, was used to measure [Ca2+]i in confluent monolayers of SH-SY5Y cells. Neither the delta-opioid agonist, DPDPE ([D-Pen2,5]-enkephalin) nor the mu-opioid agonist, DAMGO (Tyr-D-Ala-Gly-N-Me-Phe-Gly-ol enkephalin) elevated [Ca2+]i when applied alone. However, when either DPDPE or DAMGO was applied in the presence of the cholinoceptor agonist, carbachol (100 nM-1 mM) they evoked an elevation of [Ca2+]i above that caused by carbachol alone. 3. In the presence of 1 microM or 100 microM carbachol, DPDPE elevated [Ca2+]i with an EC50 of 10 nM. The elevation of [Ca2+]i was independent of the concentration of carbachol. The EC50 for DAMGO elevating [Ca2+]i in the presence of 1 microM and 100 microM carbachol was 270 nM and 145 nM respectively. 4. The delta-receptor antagonist, naltrindole (30 nM), blocked the elevations of [Ca2+]i by DPDPE (100 nM) without affecting those caused by DAMGO while the mu-receptor antagonist, CTAP (D-Phe-Cys-Tyr-D-Trp-Arg-Pen-Thr-NH2) (100 nM-1 microM) blocked the elevations of [Ca2+]i caused by DAMGO (1 microM) without affecting those caused by DPDPE. 5. Block of carbachol activation of muscarinic receptors with atropine (10 microM) abolished the elevation of [Ca2+]i by the opioids. The nicotinic receptor antagonist, mecamylamine (10 microM), did not affect the elevations of [Ca2+]i caused by opioids in the presence of carbachol. 6. Muscarinic receptor activation, not a rise in [Ca2+]i, was required to reveal the opioid response. The Ca2+ channel activator, maitotoxin (3 ng ml-1), also elevated [Ca2+]i but subsequent application of opioid in the presence of maitotoxin caused no further changes in [Ca2+]i. 7. The elevations of [Ca2+]i by DPDPE and DAMGO were abolished by pretreatment of the cells with pertussis toxin (200 ng ml-1, 16 h). This treatment did not significantly affect the response of the cells to carbachol. 8. The opioids appeared to elevate [Ca2+]i by mobilizing Ca2+ from intracellular stores. Both DPDPE and DAMGO continued to elevate [Ca2+]i when applied in nominally Ca(2+)-free external buffer or when applied in a buffer containing a cocktail of Ca2+ entry inhibitors. Thapsigargin (100 nM), an agent which discharges intracellular Ca2+ stores, also blocked the opioid elevations of [Ca2+]i. 9. delta and mu Opioids did not appear to mobilize intracellular Ca2+ by modulating the activity of protein kinases. The application of H-89 (10 microM), an inhibitor of protein kinase A, H-7 (100 microM), an inhibitor of protein kinase C, protein kinase A and cyclic GMP-dependent protein kinase, or Bis I, an inhibitor of protein kinase C, did not alter the opioid mobilization of [Ca2+]i. 10. Thus, in SH-SY5Y cells, opioids can mobilize Ca2+ from intracellular stores but they require ongoing muscarinic receptor activation. Opioids do not elevate [Ca2+]i when applied alone.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8789387      PMCID: PMC1909249          DOI: 10.1111/j.1476-5381.1996.tb15195.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  34 in total

1.  Morphine-like drugs inhibit the stimulation of E prostaglandins of cyclic AMP formation by rat brain homogenate.

Authors:  H O Collier; A C Roy
Journal:  Nature       Date:  1974-03-01       Impact factor: 49.962

Review 2.  Phosphoinositide phospholipases and G proteins in hormone action.

Authors:  J H Exton
Journal:  Annu Rev Physiol       Date:  1994       Impact factor: 19.318

3.  Pure motor hemiparesis due to hypertensive putaminal haemorrhage.

Authors:  S Jain; M C Maheshwari; R M Dhamija; N K Mishra
Journal:  Eur Neurol       Date:  1985       Impact factor: 1.710

4.  A new generation of Ca2+ indicators with greatly improved fluorescence properties.

Authors:  G Grynkiewicz; M Poenie; R Y Tsien
Journal:  J Biol Chem       Date:  1985-03-25       Impact factor: 5.157

5.  Opioid receptors in human neuroblastoma SH-SY5Y cells: evidence for distinct morphine (mu) and enkephalin (delta) binding sites.

Authors:  S M Kazmi; R K Mishra
Journal:  Biochem Biophys Res Commun       Date:  1986-06-13       Impact factor: 3.575

6.  Mu and delta opioid receptor desensitization in undifferentiated human neuroblastoma SHSY5Y cells.

Authors:  P L Prather; A W Tsai; P Y Law
Journal:  J Pharmacol Exp Ther       Date:  1994-07       Impact factor: 4.030

7.  The human delta-opioid receptor: genomic organization, cDNA cloning, functional expression, and distribution in human brain.

Authors:  F Simonin; K Befort; C Gavériaux-Ruff; H Matthes; V Nappey; B Lannes; G Micheletti; B Kieffer
Journal:  Mol Pharmacol       Date:  1994-12       Impact factor: 4.436

8.  Isoquinolinesulfonamides, novel and potent inhibitors of cyclic nucleotide dependent protein kinase and protein kinase C.

Authors:  H Hidaka; M Inagaki; S Kawamoto; Y Sasaki
Journal:  Biochemistry       Date:  1984-10-09       Impact factor: 3.162

9.  Mu-opioids activate phospholipase C in SH-SY5Y human neuroblastoma cells via calcium-channel opening.

Authors:  D Smart; G Smith; D G Lambert
Journal:  Biochem J       Date:  1995-01-15       Impact factor: 3.857

10.  Ability of delta-opioid receptors to interact with multiple G-proteins is independent of receptor density.

Authors:  P L Prather; T M McGinn; L J Erickson; C J Evans; H H Loh; P Y Law
Journal:  J Biol Chem       Date:  1994-08-19       Impact factor: 5.157

View more
  14 in total

1.  Mu and Delta opioid receptors activate the same G proteins in human neuroblastoma SH-SY5Y cells.

Authors:  A Alt; M J Clark; J H Woods; J R Traynor
Journal:  Br J Pharmacol       Date:  2002-01       Impact factor: 8.739

2.  Role of CD38, a cyclic ADP-ribosylcyclase, in morphine antinociception and tolerance.

Authors:  Lynn C Hull; Christopher Rabender; Bichoy H Gabra; Fan Zhang; Pin-Lan Li; William L Dewey
Journal:  J Pharmacol Exp Ther       Date:  2010-06-15       Impact factor: 4.030

Review 3.  Functional analysis of cloned opioid receptors in transfected cell lines.

Authors:  E T Piros; T G Hales; C J Evans
Journal:  Neurochem Res       Date:  1996-11       Impact factor: 3.996

4.  Opioid-induced down-regulation of RGS4: role of ubiquitination and implications for receptor cross-talk.

Authors:  Qin Wang; John R Traynor
Journal:  J Biol Chem       Date:  2011-01-05       Impact factor: 5.157

5.  Competition between Li+ and Mg2+ in neuroblastoma SH-SY5Y cells: a fluorescence and 31P NMR study.

Authors:  L Amari; B Layden; J Nikolakopoulos; Q Rong; D Mota de Freitas; G Baltazar; M M Castro; C F Geraldes
Journal:  Biophys J       Date:  1999-06       Impact factor: 4.033

6.  Second messenger-dependent protein kinases and protein synthesis regulate endogenous secretin receptor responsiveness.

Authors:  Roxana S Ghadessy; Eamonn Kelly
Journal:  Br J Pharmacol       Date:  2002-04       Impact factor: 8.739

7.  Modulation of Gq-protein-coupled inositol trisphosphate and Ca2+ signaling by the membrane potential.

Authors:  Daniela Billups; Brian Billups; R A John Challiss; Stefan R Nahorski
Journal:  J Neurosci       Date:  2006-09-27       Impact factor: 6.167

Review 8.  Mechanisms of cross-talk between G-protein-coupled receptors resulting in enhanced release of intracellular Ca2+.

Authors:  Tim D Werry; Graeme F Wilkinson; Gary B Willars
Journal:  Biochem J       Date:  2003-09-01       Impact factor: 3.857

9.  In vitro and in vivo pharmacological profile of UFP-512, a novel selective delta-opioid receptor agonist; correlations between desensitization and tolerance.

Authors:  B Aguila; L Coulbault; M Boulouard; F Léveillé; A Davis; G Tóth; A Borsodi; G Balboni; S Salvadori; P Jauzac; S Allouche
Journal:  Br J Pharmacol       Date:  2007-11-05       Impact factor: 8.739

10.  Co-incident signalling between mu-opioid and M3 muscarinic receptors at the level of Ca2+ release from intracellular stores: lack of evidence for Ins(1,4,5)P3 receptor sensitization.

Authors:  Damien S K Samways; Wen-hong Li; Stuart J Conway; Andrew B Holmes; Martin D Bootman; Graeme Henderson
Journal:  Biochem J       Date:  2003-11-01       Impact factor: 3.857

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.